Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China
Authors
Yuqiong Lu (ORCID: https://orcid.org/0000-0002-8175-3949)
Zhanjing Dai (ORCID: https://orcid.org/0000-0003-1481-9562)
Yang Zhou (ORCID: https://orcid.org/0000-0003-3072-271X)
Feng Chang
Yun Lu (ORCID: https://orcid.org/0000-0002-7928-7176)
Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China
Yuqiong Lu, Zhanjing Dai, Yang Zhou, Feng Chang et al.
Journal
Frontiers in Pharmacology
Topics
Lung Cancer Treatments and Mutations
article
Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China — Yuqiong Lu, Zhanjing Dai, et al. · Frontiers in Pharmacology (2025) | TGRS Research Map | TGRS